SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co.
MTC 3.230+5.6%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dan Spillane who wrote (1334)2/23/1999 10:15:00 PM
From: Anthony Wong   of 2539
 
On using Celebrex in treatment of colon cancer and alzheimer's, initial study results seem encouraging:

We have had a very active program in the research area, the
preclinical animal model area, the results of which
supported the notion that a drug such as Celebrex, a
selective COX-2 inhibitor, might have some utility there.
And we're just in the process of completing our first
clinical trial in a patient population that is highly
susceptible to developing colon polyps. We will know the
results of that study fairly soon. Assuming the outcome
will be positive, we'll be potentially moving into other
areas of colon polyp prevention.

We should know, probably by the end of the
year, whether or not the concept of using Celebrex in the
treatment of Alzheimer's has some merit. And if it does,
that would clearly be another important advance and
potential use of this class of drugs.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News